| Project/Area Number |
22790891
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Endocrinology
|
|---|
| Research Institution | National Cardiovascular Center Research Institute |
|---|
Principal Investigator |
TOKUDOME Takeshi 独立行政法人国立循環器病研究センター, 生化学部, 室長 (00443474)
|
|---|
| Research Collaborator |
SCHWENKE Daryl O. オタゴ大学, 教官
MAO Yuanjie 独立行政法人国立循環器病研究センター, 生化学部, 流動研究員
|
|---|
| Project Period (FY) |
2010 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2011: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2010: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Keywords | 内分泌学 / グレリン / ナトリウム利尿ペプチド / 心筋梗塞 / 末梢動脈閉塞性疾患 |
|---|
| Research Abstract |
We recently published that ghrelin(an orexigenic peptide) administration was able to improve malignant arrhythmia-induced mortality in acute myocardial infarction. The present study demonstrated that one dose of ghrelin improves death rate in acute phase and also prevents cardiac remodeling in myocardial infarction. Furthermore, also demonstrated that endogenous ghrelin suppressed arrhythmia-induced death through inhibition of sympathetic nerve activity and activation of parasympathetic nerve activity in acute myocardial infarcti on. These findings suggest potential usefulness of ghrelin as a therapeutic agent in myocardial infarction.
|
